Rationale for study Stromal derived factor-1α (SDF-1α) is a chemokine that has been implicated in both acute cardioprotection from ischaemia-reperfusion injury, and chronic cardioprotection by regulating stem cell migration to sites of ischaemic myocardial injury. SDF-1α has a relatively short half-life due to cleavage by dipeptidyl peptidase-4 (DPP-4) into inactive SDF-1α (3–67). However, no convenient method exists to specifically quantify active SDF-1α (1–67) in plasma, as all known antibodies recognize both the intact and cleaved forms. We describe for the first time the characterisation of a novel recombinant antibody for use in an ELISA assay for SDF-1α (1–67).
Methodology A custom antibody against the N-terminus, which is specific to the active form of SDF-1α (1–67), was identified by screening the Human Combinatorial Antibody Library (HuCAL) using a phage-display method (AbD Serotec). After further screening, the best of eight candidate antibodies was chosen and optimised as the capture antibody in a sandwich ELISA. The newly developed ELISA was used to quantify the levels of active SDF-1α (1–67) in various samples.
Results The new ELISA is both sensitive and specific for active SDF-1α (1–67). We report initial results quantifying the levels of active SDF-1α relative to cleaved, inactive SDF-1α in human and rat plasma after preconditioning and other conditions.
Conclusions We describe the development of a specific antibody for active SDF-1α (1–67) and its application in ELISA. This will increase our understanding of the kinetics and enzymatic processing of SDF-1α in acute cardioprotection and stem cell therapy.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.